Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

A Comprehensive, Evidence-Based Review of GLP-1/GIP Agonists for Fitness and Wellness Professionals ...

However, Amgen’s forward revenue guidance may also be behind the stock’s post-earnings slide. The company expects revenue to ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

and glucose-dependent insulinotropic polypeptide (GIP). When scientists discovered, in the 1990s, that incretins tell the pancreas to release insulin, they developed drugs mimicking their effects ...

Their health may improve throughout the trial, simply due to the effects of other drugs they are taking. Other factors are also at play, such as a multitude of studies or a varied patient population.

Impact on brown adipose tissue: Berberine may lower weight by increasing brown adipose tissue, a type of fat tissue that ...

Ad Meter 2025: Sign up to vote on best commercials "I think the Taylor effect, as many people call it, obviously boosted our audience," Solis says. "We love Taylor. She's a huge icon among that ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...